Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma
- Conditions
- Sarcoma
- Registration Number
- NCT02720796
- Lead Sponsor
- Champions Oncology
- Brief Summary
Patients with recurrent or metastatic sarcoma will be consented to develop a patient derived xenograft (PDX or TumorGraft) model of their tumor to perform drug sensitivity testing. The purpose of the study is to evaluate the accuracy of the patient derived xenograft (PDX) model in predicting patient clinical response to the same drug treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 17
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Number of patients' whose personalized PDX model accurately predicts clinical response to therapy with same drug treatment. 3 years Overall accuracy as assessed by evaluating Response Evaluation Criteria In Solid Tumors (RECIST) criteria in patient tumor and correlating to tumor regression in PDX model for same drug treatment.
- Secondary Outcome Measures
Name Time Method Number of patients' whose personalized PDX model accurately predicts clinical response to therapy over subsequent lines of therapy. 3 years Overall accuracy as assessed by evaluating RECIST criteria in patient and correlating to tumor regression in PDX model for same drug treatment, over subsequent lines of therapy.
Factors that impact on engraftment success. 2 years % engraftment of tumor as a function of patient and tumor characteristics.
Factors that impact time to drug sensitivity testing. 2 years Time to PDX drug sensitivity testing as a function of patient and tumor characteristics.
Trial Locations
- Locations (1)
Mount Sinai Hospital
🇨🇦Toronto, Ontario, Canada
Mount Sinai Hospital🇨🇦Toronto, Ontario, Canada